1-12 of 12
Andrew X. Zhu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT185: Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC

Peter R. Galle, Richard S. Finn, Ann-Lii Cheng, Coen Bernaards, Colby S. Shemesh, Alexandr Vilimovskij, Wendy J. Verret, Sven F. Stanzel, Ning Ma, Michel Ducreux, Andrew X. Zhu
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT185.
https://doi.org/10.1158/1538-7445.AM2021-CT185
Published: 01 July 2021
View article titled, Abstract CT185: Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC
Journal Articles

Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Ho Yeong Lim, Valeriy Breder, Philippe Merle, Ahmed Kaseb, Daneng Li, Yin-Hsun Feng, Wendy Verret, Alan Nicholas, Lindong Li, Ning Ma, Andrew X. Zhu, Ann-Lii Cheng
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT009.
https://doi.org/10.1158/1538-7445.AM2021-CT009
Published: 01 July 2021
View article titled, Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
Journal Articles

Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)

Andrew X. Zhu, Yinghui Guan, Alexander R. Abbas, Hartmut Koeppen, Shan Lu, Chih-Hung Hsu, Kyung-Hun Lee, Michael S. Lee, Aiwu Ruth He, Amit Mahipal, Beiying Ding, Jessica Spahn, Wendy Verret, Baek-Yeol Ryoo, Yulei Wang
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT044.
https://doi.org/10.1158/1538-7445.AM2020-CT044
Published: 15 August 2020
View article titled, Abstract CT044: Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)
Journal Articles

Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency

Chi Luo, Jiaxin Liang, Kfir Sharabi, Maximilian Hatting, Elizabeth A. Perry, Clint D.J. Tavares, Lipika Goyal, Amitabh Srivastava, Marc Bilodeau, Andrew X. Zhu, Piotr Sicinski, Pere Puigserver
Journal: Cancer Research
Cancer Res (2020) 80 (16): 3215–3221.
https://doi.org/10.1158/0008-5472.CAN-20-0106
Published: 14 August 2020
View article titled, Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency
Open the PDF for Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency in another window
Includes: Supplementary data
Journal Articles

Abstract CT061: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results

Masafumi Ikeda, Max W. Sung, Masatoshi Kudo, Masahiro Kobayashi, Ari D. Baron, Richard S. Finn, Shuichi Kaneko, Andrew X. Zhu, Tomoki Kubota, Silvija Kralijevic, Hiroki Ikezawa, Abby B. Siegel, Hiromitsu Kumada, Takuji Okusaka
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT061.
https://doi.org/10.1158/1538-7445.AM2019-CT061
Published: 01 July 2019
View article titled, Abstract CT061: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Journal Articles

Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers

Aparna R. Parikh, Ignaty Leshchiner, Liudmila Elagina, Lipika Goyal, Chaya Levovitz, Giulia Siravegna, Dimitri Livitz, Kahn Rhrissorrakrai, Liz Martin, Emily E. Van Seventer, Megan Hanna, Kara Slowik, Filippo Utro, Christopher J. Pinto, Alicia Wong, Brian P. Danysh, Ferran Fece de la Cruz, Isobel J. Fetter, Brandon Nadres, Heather A. Shahzade, Jill N. Allen, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Bruce Giantonio, Janet E. Murphy, Ryan D. Nipp, Eric Roeland, David P. Ryan, Colin D. Weekes, Eunice L. Kwak, Jason E. Faris, Francois Aguet, Ipsita Guha, Mehlika Hazar-Rethinam, Dora Dias-Santagata, David T. Ting, Andrew X. Zhu, Theodore S. Hong, Todd R. Golub, A J. Iafrate, Viktor Adalsteinsson, Alberto Bardelli, Laxmi Parida, Dejan Juric, Gad Getz, Ryan B. Corcoran
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-257.
https://doi.org/10.1158/1538-7445.AM2019-LB-257
Published: 01 July 2019
View article titled, Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers
Journal Articles

Abstract LB-092: TAS120, a covalently-binding FGFR inhibitor (FGFRi), overcomes resistance to BGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma

Lipika Goyal, Leah Y. Liu, Jochen K. Lennerz, James J. Harding, Jerry Huang, Robert Winkler, Hirai Hiroshi, David T. Ting, Dejan Juric, Ryan B. Corcoran, Nabeel El-Bardeesy, Andrew X. Zhu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-092.
https://doi.org/10.1158/1538-7445.AM2018-LB-092
Published: 01 July 2018
View article titled, Abstract LB-092: TAS120, a covalently-binding FGFR inhibitor (FGFRi), overcomes resistance to BGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma
Journal Articles

Abstract 4114: Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients

Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Benedetta Mussolin, Stephanie Reyes, Pascal Furet, A. John Iafrate, Gad Getz, Diana G. Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4114.
https://doi.org/10.1158/1538-7445.AM2017-4114
Published: 01 July 2017
View article titled, Abstract 4114: Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients
Journal Articles

Abstract 1734: Absolute quantification of circulating tumor cell RNA enables high specificity detection of hepatocellular carcinoma

Mark Kalinich, Irun Bhan, Tanya T. Kwan, David T. Miyamoto, Sarah Javaid, Joseph A. LiCausi, John D. Milner, Xin Hong, Lipika Goyal, Srinjoy Sil, Melissa Choz, Ravi Kapur, Alona Muzikansky, Huidan Zhang, David A. Weitz, Lecia V. Sequist, David P. Ryan, Raymond Chung, Andrew X. Zhu, Kurt J. Isselbacher, David T. Ting, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1734.
https://doi.org/10.1158/1538-7445.AM2017-1734
Published: 01 July 2017
View article titled, Abstract 1734: Absolute quantification of circulating tumor cell RNA enables high specificity detection of hepatocellular carcinoma
Journal Articles

Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression

Stephen L. Chan, Chia-Jui Yen, Martin Schuler, Chia-Chi Lin, Su Pin Choo, Karl-Heinz Weiss, Andreas Geier, Takuji Okusaka, Ho Yeong Lim, Teresa Macarulla, Andrew X. Zhu, Tomoyuki Kakizume, Yi (Gary) Gu, Diana Graus Porta, Andrea P. Myers, Jean-Pierre Delord
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT106.
https://doi.org/10.1158/1538-7445.AM2017-CT106
Published: 01 July 2017
View article titled, Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression
Journal Articles

KrasG12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma

Michael R. O'Dell, Jing Li Huang, Christa L. Whitney-Miller, Vikram Deshpande, Paul Rothberg, Valerie Grose, Randall M. Rossi, Andrew X. Zhu, Hartmut Land, Nabeel Bardeesy, Aram F. Hezel
Journal: Cancer Research
Cancer Res (2012) 72 (6): 1557–1567.
https://doi.org/10.1158/0008-5472.CAN-11-3596
Published: 14 March 2012
View article titled, <em>Kras<sup>G12D</sup></em> and <em>p53</em> Mutation Cause Primary Intrahepatic Cholangiocarcinoma
Open the PDF for <em>Kras<sup>G12D</sup></em> and <em>p53</em> Mutation Cause Primary Intrahepatic Cholangiocarcinoma in another window
Journal Articles

Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells

Bryan C. Fuchs, Tsutomu Fujii, Jon D. Dorfman, Jonathan M. Goodwin, Andrew X. Zhu, Michael Lanuti, Kenneth K. Tanabe
Journal: Cancer Research
Cancer Res (2008) 68 (7): 2391–2399.
https://doi.org/10.1158/0008-5472.CAN-07-2460
Published: 01 April 2008
View article titled, Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
Open the PDF for Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells in another window